|
| Press Releases |
|
 |
|
| Friday, October 21, 2016 |
|
|
Nanobiotix's Partner, PharmaEngine, Has Launched a New NBTXR3 Clinical Trial in Head and Neck Cancers in Asia |
| NANOBIOTIX, a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announced that its Asia-Pacific partner, PharmaEngine, has dosed its first patient in a new Phase I/II trial in patients with head and neck cancers patient receiving radiotherapy plus chemotherapy, this October. more info >> |
|
| Tuesday, October 4, 2016 |
|
|
Nanobiotix Strengthens U.S. Leadership with Appointments of Head of U.S. Clinical Development and Director of Investor Relations |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announced that it has strengthened its U.S. leadership team with the appointments of Dr. Mihail Obrocea as the Head of U.S. Clinical Development and Noel Kurdi as the Director of Investor Relations. more info >> |
|
| Tuesday, September 20, 2016 |
|
|
Bpifrance Grants Nanobiotix a 2M EUR Interest-free Loan to Support Final Development Stage of Lead Product, NBTXR3 |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announced today that Bpifrance has awarded the Company an interest-free loan of EUR 2M for Innovation (pret a taux zero pour l'Innovation - PTZI). more info >> |
|
| Wednesday, September 14, 2016 |
|
|
Nanobiotix Announces Submission for First Market Approval of Lead Product NBTXR3 in Europe |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, has filed for market approval (CE Marking) in Europe for its lead product, a first-in-class radio-enhancer, NBTXR3. more info >> |
|
| Thursday, July 7, 2016 |
|
|
Nanobiotix Reports Successful Results from Phase I/II Trial of NBTXR3 in Head & Neck Cancer |
| NANOBIOTIX, a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announced positive results from a Phase I/II clinical trial of its lead product, NBTXR3, for the treatment of locally advanced cancers of the oral cavity, tongue or oropharynx (head and neck cancer, or H&N) in frail and elderly patients. more info >> |
|
| Tuesday, May 31, 2016 |
|
|
Nanobiotix Establishes Promising Preclinical Proof-of-Concept in Immuno Oncology |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today that the Company has established preliminary preclinical proof-of-concept (POC) with the lead product NBTXR3 for its new program in Immuno Oncology (IO). more info >> |
|
| Friday, April 29, 2016 |
|
|
Nanobiotix: 2015 Annual Results |
| Nanobiotix (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces its audited consolidated results for the fiscal year ended December 31, 2015. more info >> |
|
| Tuesday, January 5, 2016 |
|
|
Nanobiotix Starts a New Research Program, in Immuno Oncology, with Its Lead Product NBTXR3 |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today that, in addition to its current advanced clinical development program, the Company has started exploring the use of NBTXR3 for combination in Immuno Oncology. more info >> |
|
| Thursday, July 2, 2015 |
|
|
Nanobiotix starts Phase I/II clinical trial in liver Metastasis and Hepatocellular Cancer with its lead product NBTXR3 |
| Nanobiotix (Euronext: NANO), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, has been authorized to begin a new clinical trial in liver cancers for its lead NanoXray product, NBTXR3. more info >> |
|
| Wednesday, June 10, 2015 |
|
|
Nanobiotix Reports Positive Preliminary Results in Head and Neck Cancer Phase I/II Clinical Trial with NBTXR3 |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces positive preliminary safety results for its lead NanoXray product NBTXR3, in its head and neck cancer Phase I/II clinical trial. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Campaign to promote Hong Kong's advantages in professional services in Vietnam
Aug 11, 2025 15:03 HKT/SGT
|
|
|
31 Concept to Debut Patent-Pending Technology at ISS Asia 2025 in Singapore
Aug 11, 2025 13:13 HKT/SGT
|
|
|
31 Concept將在2025年新加坡ISS Asia首度發佈其申請專利的新技術
Aug 11, 2025 13:13 HKT/SGT
|
|
|
Qube Celebrates 20 Years of Business Events Impact with Industry Recognition and Vision for the Future
Aug 11, 2025 12:03 HKT/SGT
|
|
|
TransNusa Focuses on Organic Growth to Strengthen Network Connectivity in China
Aug 11, 2025 11:00 HKT/SGT
|
|
|
沙烏地電力公司2025年第二季淨利成長22%
Aug 11, 2025 11:00 HKT/SGT
|
|
|
Cryofocus Medtech Achieves Record Interim Results with 162% Revenue Surge Driven by Respiratory Intervention Products
Aug 11, 2025 10:41 HKT/SGT
|
|
|
康灃生物中期業績創紀錄 呼吸介入產品驅動收入激增162%
Aug 11, 2025 10:41 HKT/SGT
|
|
|
康沣生物中期业绩创纪录 呼吸介入产品驱动收入激增162%
Aug 11, 2025 10:41 HKT/SGT
|
|
|
Shoucheng-Backed Data Center REITs Surge on Market Debut
Aug 11, 2025 09:00 HKT/SGT
|
|
|
首批數據中心REITs上市首日雙雙漲停 首程控股再顯產業資本實力
Aug 11, 2025 09:00 HKT/SGT
|
|
|
首批数据中心REITs上市首日双双涨停 首程控股再显产业资本实力
Aug 11, 2025 09:00 HKT/SGT
|
|
|
Natural Beauty 2025 Interim Profit Surges by 136% to HK$11 Million
Aug 11, 2025 08:15 HKT/SGT
|
|
|
Intellifusion Submits an Application to List on the Hong Kong Stock Exchange: A National Breakthrough in AI Inference Chips
Aug 11, 2025 08:07 HKT/SGT
|
|
|
Everest Medicines Announces Full Approval of NEFECON(R) in Taiwan
Aug 11, 2025 07:37 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
